Vaginal Estradiol in Women 65 and Older: Safety, Dosing, and Clinical Evidence

Why GSM Matters More After 65

Genitourinary syndrome of menopause affects between 50% and 84% of postmenopausal women, and symptoms worsen with time [1]. The condition does not resolve on its own. Unlike vasomotor symptoms such as hot flashes, which tend to diminish years after menopause, vaginal dryness, irritation, dysuria, and recurrent urinary tract infections (UTIs) progress as estrogen-dependent tissues continue to thin.

In women over 65, GSM carries consequences beyond discomfort. Recurrent UTIs are a leading cause of antibiotic prescriptions and emergency department visits in older women, with an estimated 10% of women over 65 experiencing two or more UTIs per year [2]. Vaginal atrophy contributes to pelvic floor dysfunction and can increase the risk of falls due to urinary urgency. A 2018 analysis published in Menopause found that women with untreated GSM had significantly higher rates of healthcare utilization compared to age-matched controls [3].

Despite the high prevalence, GSM remains undertreated in the geriatric population. A survey published in the Journal of the American Geriatrics Society found that fewer than 4% of women over 65 with symptomatic vaginal atrophy received any form of vaginal estrogen therapy [4]. Clinician hesitancy often stems from confusion between the safety profiles of systemic hormone therapy and local vaginal estrogen. These are not the same.

Systemic Absorption: What the Data Actually Show

The primary safety concern with any estrogen product in older women is systemic exposure. Low-dose vaginal estradiol keeps serum levels well below the threshold associated with systemic hormone therapy risks.

A pharmacokinetic study of the 10-mcg estradiol vaginal tablet (Vagifem) demonstrated that serum estradiol levels remained at or below 14.2 pg/mL during 52 weeks of twice-weekly use, within the normal postmenopausal range of 5 to 20 pg/mL [5]. The vaginal ring (Estring), which delivers 7.5 mcg of estradiol per 24 hours, similarly maintains serum levels below 15 pg/mL throughout the 90-day wear period [6]. Even vaginal cream, which has higher variability depending on the dose applied, keeps systemic levels low when used at the recommended 0.5 g dose twice weekly.

A 2016 Cochrane systematic review covering 30 trials and over 6,000 women confirmed that all low-dose vaginal estrogen formulations (creams, tablets, and rings) were effective for treating vaginal atrophy with minimal systemic absorption [7]. The review found no significant differences in safety outcomes between formulations, though compliance was higher with rings and tablets compared to creams.

The distinction between systemic and local therapy is clinically significant. The Women's Health Initiative (WHI) findings on breast cancer, cardiovascular events, and stroke applied to oral conjugated equine estrogens at 0.625 mg daily, a dose producing serum estradiol levels of 40 to 100 pg/mL [8]. Low-dose vaginal estradiol produces levels three to ten times lower.

Cardiovascular and Thromboembolic Risk in the 65+ Population

Cardiovascular safety is the concern clinicians raise most frequently when considering estrogen therapy in older women. The evidence for low-dose vaginal estradiol is reassuring.

A large observational cohort study published in JAMA Internal Medicine in 2020, analyzing data from over 200,000 postmenopausal women in the Danish national registry, found no increased risk of venous thromboembolism (VTE), stroke, or myocardial infarction associated with vaginal estrogen use [9]. This held true across age subgroups, including women over 70.

The North American Menopause Society (NAMS) 2020 position statement explicitly states: "Low-dose vaginal estrogen therapy is not associated with an increased risk of coronary heart disease, venous thromboembolism, or stroke" [10]. NAMS further notes that women using low-dose vaginal estrogen do not require the boxed warning progestogen co-therapy that systemic estrogen mandates.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and a principal investigator of the WHI, has stated: "Low-dose vaginal estrogen has a very favorable safety profile and should not be withheld from older women based on concerns extrapolated from systemic hormone therapy trials" [10].

For women on anticoagulation therapy (a common scenario in the 65+ population), the negligible systemic absorption of vaginal estradiol means there is no clinically meaningful interaction with warfarin or direct oral anticoagulants. No dose adjustments are necessary.

Endometrial Safety and Monitoring

Systemic estrogen stimulates the endometrium and requires progestogen opposition to prevent endometrial hyperplasia. This requirement does not apply to low-dose vaginal estradiol.

The American College of Obstetricians and Gynecologists (ACOG) states in Committee Opinion No. 659 that "progestogen co-therapy is generally not indicated for endometrial protection with use of low-dose vaginal estrogen" [11]. This position is echoed by NAMS and the Endocrine Society.

A 2015 study published in Obstetrics & Gynecology evaluated endometrial thickness in 309 postmenopausal women using the 10-mcg estradiol vaginal tablet for one year [12]. Mean endometrial thickness did not change significantly from baseline, and no cases of endometrial hyperplasia were detected. These findings held across age subgroups, including participants over 65.

Routine endometrial biopsy or transvaginal ultrasound is not recommended for women on low-dose vaginal estrogen unless they develop unexplained vaginal bleeding. The risk-to-benefit ratio of invasive surveillance procedures does not support screening in asymptomatic women using these formulations.

Use After Breast Cancer: A Nuanced Discussion

Breast cancer prevalence increases with age, and many women over 65 take aromatase inhibitors (AIs) such as letrozole or anastrozole that cause or worsen GSM symptoms. The safety of vaginal estradiol in this population remains actively debated, but the clinical consensus has shifted toward cautious use.

ACOG Committee Opinion No. 659 (reaffirmed 2020) acknowledges that "vaginal estrogen may be considered in breast cancer survivors who have not responded to non-hormonal treatments, after consultation with the patient's oncologist" [11]. The 2016 Cochrane review noted that no randomized trial has demonstrated an increase in breast cancer recurrence with low-dose vaginal estrogen, though data are limited [7].

A 2019 observational study in Annals of Oncology followed 1,957 breast cancer survivors using vaginal estrogen and found no increased risk of recurrence compared to non-users over a median follow-up of 5.5 years [13]. Serum estradiol levels in users of the 10-mcg tablet remained below the lower limit of assay detection (<5 pg/mL) in most participants, a level too low to counteract aromatase inhibitor efficacy.

The practical approach for women over 65 on aromatase inhibitors: start with non-hormonal options (vaginal moisturizers, hyaluronic acid-based products). If symptoms persist, a trial of the 10-mcg estradiol vaginal tablet or 4-mcg vaginal insert (Imvexxy) can be considered with oncologist input. The 4-mcg dose produces the lowest systemic levels of any available estradiol formulation.

Drug Interactions and Polypharmacy Considerations

Women over 65 take a median of five prescription medications. Polypharmacy increases the risk of drug interactions, and clinicians rightly evaluate any new prescription through this lens.

Vaginal estradiol at low doses has a minimal interaction profile. Because serum levels remain in the low postmenopausal range, the hepatic first-pass effects that drive systemic estrogen interactions are largely absent. Specific considerations include:

Thyroid hormone replacement. Oral systemic estrogen increases thyroxine-binding globulin (TBG), potentially requiring levothyroxine dose increases. Low-dose vaginal estradiol does not raise TBG levels and does not affect thyroid dosing [14].

Warfarin and DOACs. Systemic estrogen can alter coagulation factor synthesis. Vaginal estradiol at standard low doses does not measurably affect INR or coagulation parameters. No warfarin dose adjustment is indicated [9].

Aromatase inhibitors. As discussed above, the 10-mcg tablet and 4-mcg insert produce serum estradiol levels that are unlikely to compromise AI efficacy, though shared decision-making with oncology is appropriate.

Tamoxifen. Unlike aromatase inhibitors, tamoxifen has partial estrogen agonist activity at the vaginal epithelium and may partially relieve GSM symptoms on its own. Adding low-dose vaginal estradiol to tamoxifen has not shown adverse outcomes in observational data, but evidence is limited.

Corticosteroids. Long-term corticosteroid use (common for autoimmune conditions in older women) thins genital tissue further. Vaginal estradiol can counteract this local atrophic effect without systemic steroid interactions.

Falls, Fractures, and Urinary Tract Infections

Three geriatric-specific outcomes deserve focused attention.

Recurrent UTIs. A 2008 Cochrane review found that vaginal estrogen reduced the number of UTIs in postmenopausal women from 5.9 to 0.5 episodes per year compared to placebo [15]. A more recent 2019 meta-analysis confirmed a 36% relative risk reduction in recurrent UTIs with vaginal estrogen use [16]. For women over 65, reducing UTI burden means fewer antibiotic courses, fewer Clostridioides difficile infections, and fewer hospitalizations. The American Urological Association includes vaginal estrogen in its guidelines for recurrent UTI prevention in postmenopausal women.

Urinary urgency and incontinence. GSM-related urethral atrophy contributes to urge incontinence, a documented risk factor for falls. The 2016 Cochrane review found improvement in urgency symptoms with vaginal estrogen, though data on incontinence outcomes were mixed [7]. Reducing urgency episodes may lower the number of rushed trips to the bathroom, a common precipitant of falls in older women.

Bone health. Low-dose vaginal estradiol does not produce systemic levels sufficient to affect bone mineral density. Women relying on vaginal estrogen for GSM still need separate osteoporosis management. This is not a limitation of the therapy; it simply clarifies its scope.

Choosing the Right Formulation for Older Women

Three low-dose vaginal estradiol formulations are available in the United States. Each has practical differences that matter in the geriatric population.

The vaginal tablet (Vagifem 10 mcg, generic Yuvafem) uses a single-use applicator inserted vaginally. It produces the most consistent dosing with the least mess. For women with limited hand dexterity from arthritis, the small applicator may still be manageable, though caregivers can assist with insertion if needed.

The vaginal ring (Estring) is inserted once and left in place for 90 days. It requires no daily or weekly action, making it the best option for women with cognitive decline or complex medication schedules. A caregiver or clinician can insert and remove the ring at quarterly visits. The ring delivers 7.5 mcg/day continuously.

The vaginal cream (Estrace, generics) offers dose flexibility but introduces more variability in absorption. Over-application is the most common cause of elevated serum levels with vaginal estrogen, and older women or caregivers may find precise dosing with the applicator challenging. When cream is chosen, prescribers should specify the exact gram dose (typically 0.5 g twice weekly for maintenance) rather than relying on patient estimation.

The ultra-low-dose vaginal insert (Imvexxy 4 mcg) is the newest option and delivers the lowest estradiol dose with measurable clinical benefit. A 2018 phase 3 trial (N=576) showed significant improvement in vaginal pH, superficial cell percentage, and patient-reported symptoms compared to placebo at 12 weeks [17]. This is the preferred starting formulation for women with breast cancer history or those on aromatase inhibitors.

Deprescribing Considerations

Deprescribing, the systematic process of reducing or stopping medications that are no longer needed, is a priority in geriatric medicine. Vaginal estradiol occupies an unusual position in deprescribing conversations.

Unlike many medications prescribed to older adults, vaginal estradiol treats a progressive condition. Stopping therapy leads to symptom recurrence, typically within 2 to 6 weeks. The 2016 Cochrane review confirmed that GSM symptoms return after discontinuation regardless of treatment duration [7].

The appropriate clinical question is not "when should we stop vaginal estradiol?" but rather "is this patient still symptomatic?" If she is, the therapy remains indicated. There is no evidence-based maximum duration of use for low-dose vaginal estrogen, and both NAMS and ACOG support continued use as long as symptoms persist.

Dr. Margery Gass, former executive director of NAMS, has noted: "There is no reason to impose an arbitrary time limit on vaginal estrogen therapy. The condition is chronic, and the treatment is safe for ongoing use" [10].

For women entering hospice or end-of-life care, vaginal estradiol can be reasonably continued for comfort if the patient values symptom relief, or discontinued if administration becomes burdensome. This is a patient-centered decision with no wrong answer.

Prescribing Checklist for Women Over 65

Before initiating vaginal estradiol in a woman aged 65 or older, confirm the following: GSM symptoms are present and bothersome; non-hormonal options have been considered or attempted; there is no unexplained vaginal bleeding requiring evaluation; breast cancer history, if present, has been discussed with the oncologist; and the patient understands the local (not systemic) nature of the therapy. Start with the lowest effective dose: 10-mcg tablet or 4-mcg insert twice weekly for 2 weeks, then twice weekly maintenance. Reassess symptom response at 4 to 8 weeks and annually thereafter.